作者: Graham D. Burrows , Kay P. Maguire , Trevor R. Norman
DOI:
关键词: Psychology 、 Antidepressant 、 Reuptake inhibitor 、 Tolerability 、 Reboxetine 、 Hamilton Rating Scale for Depression 、 Adverse effect 、 Internal medicine 、 Major depressive disorder 、 Anesthesia 、 Clinical trial
摘要: Reboxetine is a unique selective norepinephrine reuptake inhibitor (NRI) with proven antidepressant efficacy in pharmacologic and biochemical tests predictive of properties. Comprehensive clinical trials, including 8 placebo-controlled and/or active treatment-controlled studies, plus 4 open have assessed the short-term long-term tolerability reboxetine patients major depressive disorders dysthymia. Results from total 690 who entered 5 or studies are summarized this paper. Four hundred forty-nine diagnosis either disorder dysthymia were treated these weeks' to 12 months' duration. In 6-week study, clinically significant improvement (≥ 50% reduction Hamilton Rating Scale for Depression score) was observed at last assessment 74% reboxetine-treated compared 20% placebo group. Similar results run-in phases 3 where maintained over 12-month study period. well tolerated; adverse events reported mainly mild moderate severity, there no changes vital signs laboratory parameters. The first its class, reboxetine, NRI, will provide valuable addition existing armamentarium agents used treatment depression.